Back to search results

Observational Study of Stenting for Ischemic Strokes Caused by ICAD

This study is looking at how well a procedure called intracranial stenting works for people who have had an ischemic stroke (a stroke caused by a blood clot) due to Intracranial Atherosclerotic Disease (ICAD). ICAD is a condition where the arteries in your brain narrow. You might be able to join if you are an adult who has experienced a stroke despite trying other medical treatments, and your arteries are 70-99% narrowed. The study will follow about 150 participants to see if stenting helps prevent future strokes, bleeding in the brain (ICH), or death. Researchers will collect information about your health and the stenting procedure to understand current treatment practices and outcomes.

Study design
This is an observational study, meaning researchers will collect information from about 150 patients who undergo intracranial stenting as part of their regular care. It is not a randomized trial.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
Participants will be followed for outcomes such as recurrent stroke, bleeding in the brain, or death at 72 hours post-procedure, and again at 6 months to 1 year after the procedure.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06790147

Stenting for Ischemic Strokes Secondary to Medically Refractory Intracranial Atherosclerotic Disease

Not Yet Recruiting
Not specifiedAges 18+Observational
Nitin Goyal
~150 participants
Updated 2025-05-16 on ClinicalTrials.gov

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Recurrent ischemic stroke within treated territory, ICH, or death
Measured over 72 hours post procedure
+1 more outcome measured

Conditions

ICAD - Intracranial Atherosclerotic Disease
Ischemic Stroke

Explore related trials

Cerebral AtherosclerosisIschemic Stroke

NCT06790147

Where you'd take part

This study runs at 1 site. They're the same protocol — you choose where, and that choice sets who your contact draft is addressed to.

  • Semmes Murphey Clinic

    Memphis, Tennesseestudy coordinator listed

Sites open and close at different times, so the status above is per site — it can differ from the study's overall status.

Study leadership

  • Nitin Goyal, MD · PRINCIPAL_INVESTIGATOR · Semmes Murphey Clinic
  • Violiza Inoa, MD · PRINCIPAL_INVESTIGATOR · Semmes Murphey Clinic

Who to contact

Nitin Goyal, MD
[email protected]
901-522-7700
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Want this trial checked against your situation?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Adult patients with ICAD resulting in 70-99% vessel stenosis who undergo PTAS with any device
Patients will have to experience a stroke despite medical management involving risk factor modification and an antiplatelet agent
Baseline modified Rankin Scale (mRS) ≤ 3
Performance of the endovascular procedure at least 3 days after the last stroke

Exclusion

Large vessel occlusion strokes undergoing rescue intracranial stenting will not be included
Baseline modified Rankin Scale (mRS) \>3
Performance of the endovascular procedure less than 3 days after the last stroke.
Patients undergoing intracranial stenting for first stroke caused by ICAD
Adult patients with ICAD resulting in \<70% vessel stenosis

What this trial measures

  • Recurrent ischemic stroke within treated territory, ICH, or death72 hours post procedure

    Recurrent ischemic stroke within the territory treated, intracranial hemorrhage, or death within 72 hours after the procedure. All of the patients enrolled in the trial will be assessed at 72 hours post-stenting either in the hospital by the study interventionalist or, if the patient had already been discharged home, by telephone interview by a core study nurse or interventionalist.

  • Stroke, ICH, or neurological death in treated territory6 months to 1 year post procedure

    Stroke within the territory treated, intracranial hemorrhage, or neurologic death within 6 months to 1 year after PTAS. All the patient enrolled in the trial will undergo * Follow up clinic visit between 6 months to 1 year per standard of care * Follow up vascular imaging (modality of imaging will be decided based on standard of care at participating centers)